A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ
Phase of Trial: Phase I/II
Latest Information Update: 01 Jul 2018
At a glance
- Drugs CLL 442 (Primary)
- Indications Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 Apr 2018 Planned End Date changed from 6 Feb 2019 to 3 Apr 2019.
- 02 Apr 2018 Planned primary completion date changed from 6 Feb 2019 to 3 Apr 2019.
- 02 Apr 2018 Status changed from not yet recruiting to recruiting.